Checkpoint Capital L.P. Rhythm Pharmaceuticals, Inc. Transaction History
Checkpoint Capital L.P.
- $166 Billion
- Q2 2024
A detailed history of Checkpoint Capital L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 922,100 shares of RYTM stock, worth $47.8 Million. This represents 22.82% of its overall portfolio holdings.
Number of Shares
922,100
Previous 825,500
11.7%
Holding current value
$47.8 Million
Previous $35.8 Billion
5.85%
% of portfolio
22.82%
Previous 23.91%
Shares
3 transactions
Others Institutions Holding RYTM
# of Institutions
178Shares Held
69.1MCall Options Held
467KPut Options Held
224K-
Primecap Management CO Pasadena, CA7.31MShares$379 Million0.22% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$350 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$332 Million3.49% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$316 Million3.77% of portfolio
-
Goldman Sachs Group Inc New York, NY5.29MShares$274 Million0.04% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.89B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...